Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 20/20 | 0.62 |
| ▸ | TDO2 | P48775 | 7/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20621023 | 1.00 | IDO1 (0.62) | IDO1TDO2CYP3A4CYP2D6CYP2B6 | |
| SCHEMBL20602751 | 1.00 | IDO1 (0.62) | IDO1TDO2CYP3A4CYP2D6CYP2B6 | |
| SCHEMBL20602670 | 0.90 | IDO1 (0.58) | IDO1TDO2CYP3A4CYP2D6CYP2B6 | |
| SCHEMBL20602698 | 0.88 | IDO1 (0.55) | IDO1TDO2 | |
| SCHEMBL20602636 | 0.84 | IDO1 (0.56) | IDO1TDO2 | |
| SCHEMBL20602787 | 0.84 | IDO1 (0.50) | IDO1TDO2 | |
| SCHEMBL20602800 | 0.83 | IDO1 (0.53) | IDO1TDO2 | |
| SCHEMBL30649003 | 0.82 | IDO1 (0.54) | IDO1TDO2 | |
| SCHEMBL20602817 | 0.82 | IDO1 (0.54) | IDO1TDO2 | |
| SCHEMBL30649299 | 0.82 | IDO1 (0.52) | IDO1TDO2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827639-B2 | TDO2 and IDO1 inhibitors | GENENTECH, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11827639-B2 | TDO2 and IDO1 inhibitors | GENENTECH, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20200216456-A1 | TDO2 and IDO1 Inhibitors | GENENTECH, INC. | 2020-07-09 | — | — | US | disclosed |
| WO-2019006047-A1 | TDO2 AND IDO1 INHIBITORS | GENENTECH, INC. (US) | 2019-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200216456-A1 | TDO2 and IDO1 Inhibitors | IDO1, IDO2, TDO2 | IDO1 1/4885TDO2 3/4885CYP3A4 430/4885 |
| US-11827639-B2 | TDO2 and IDO1 inhibitors | IDO1, TDO2, IDO2 | IDO1 1/4885TDO2 2/4885CYP3A4 428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.